Isotope-Only Localization for Sentinel Lymph Node Biopsy - Medium-Term Oncological Outcomes.
Loading...
Embargo End Date
ICR Authors
Authors
Micha, A
Parvaiz, MA
O'Riordan, L
MacNeill, F
Rusby, JE
Parvaiz, MA
O'Riordan, L
MacNeill, F
Rusby, JE
Document Type
Journal Article
Date
2022-07-01
Date Accepted
2022-02-25
Abstract
AIMS: Isotope and blue dye dual localization in sentinel lymph node biopsy (SLNB) gives localization rates of over 98% and is the recommended technique. However blue dye risks a range of adverse reactions. Since 2010, for clinically node negative disease, we have only used blue dye if there is no clear isotope signal at surgery. METHODS: Electronic records of patients who underwent isotope-only SLN localization between July 2010 and April 2012 were examined. Data were collected on localization and oncological outcomes. RESULTS: 426 patients were included. Isotope-only localization rate was 97.4% (415/426). The median follow-up was 63.5 months (IQR: 60.7-70.9). Median age was 57 (IQR: 48-67). Median SLN yield was 2 (range: 1-5). Axillary recurrence rate was 1.4% with median time to recurrence of 39.3 months. In-breast recurrence, distant disease and contralateral breast cancer rates were 2.8%, 7%, and 1.9% respectively and 15 (3.5%) patients died of metastatic breast cancer. CONCLUSION: Isotope-only SLNB has a comparable localization rate to dual isotope/blue dye SLNB and can spare the risk of blue dye adverse reactions. The low axillary recurrence rate, maintained to more than 5 years, confirms that isotope-only SLNB is a feasible and safe alternative to dual blue dye/isotope localization.
Citation
Clinical breast cancer, 2022
Source Title
Publisher
CIG MEDIA GROUP, LP
ISSN
1526-8209
eISSN
1938-0666